Trinity Partners Unveils 2016 Predictions for the Biopharmaceutical Industry

Drug pricing and biosimilars in light of the upcoming Presidential election:

Thanks to recent media uproar around companies like Turing Pharmaceuticals, the company that upped the price of a life-saving drug for parasitic infection by 5,000 percent, drug pricing is expected to be a huge topic around the presidential election over the next year with candidates sharing proposals to help address this issue. This will also likely bring continued attention to biosimilars, which are drugs designed to have properties similar to biologics that have previously been approved. In the next year, close attention will be paid to their rate of adoption in the US compared to the past uptake of generics, especially given obstacles such as pricing, strict regulations and questions around marketing.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s